Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Target Price
The average target price of PROF is 12 and suggests 67% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell